The envelope protein (Env) is the only surface protein of the human immunodeficiency virus (HIV) and as such the exclusive target for protective antibody responses. Experimental evidences from mouse models suggest a modulating property of Env to steer antibody class switching towards the less effective antibody subclass IgG1 accompanied with strong TH2 helper responses. By simple physical linkage we were able to imprint this bias, exemplified by a low IgG2a/IgG1 ratio of antigen-specific antibodies, onto an unrelated antigen, namely the HIV capsid protein p24. Here, our results indicate the glycan moiety of Env as the responsible immune modulating activity. Firstly, in Card9−/− mice lacking specific C-Type lectin responsiveness,...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
AbstractThe Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against hum...
The envelope protein (Env) is the only surface protein of the human immunodeficiency virus (HIV) and...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
HIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that...
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The ...
AbstractThe HIV-1 envelope glycoprotein complex (Env) is the focus of vaccine development aimed at e...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
<div><p>The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free hole...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
AbstractThe Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against hum...
The envelope protein (Env) is the only surface protein of the human immunodeficiency virus (HIV) and...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
The HIV-1 envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bn...
HIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that...
The HIV envelope glycoprotein (Env) is extensively modified with host-derived N-linked glycans. The ...
AbstractThe HIV-1 envelope glycoprotein complex (Env) is the focus of vaccine development aimed at e...
© 2017 Dr Christopher Andrew GonelliA prophylactic vaccine eliciting broadly neutralising antibody (...
Thesis (Ph.D.)--University of Washington, 2016-03HIV-1 establishes persistent infection in part due ...
<div><p>The extensive glycosylation of HIV-1 envelope (Env) glycoprotein leaves few glycan-free hole...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
Prophylactic HIV vaccines must elicit antibodies (Abs) against the virus envelope glycoproteins (Env...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
This work is licensed under a Creative Commons Attribution Non-Commercial-No Derivatives 4.0 Interna...
AbstractThe Env glycoproteins gp120 and gp41 are used in humoral immunity-based vaccines against hum...